FDA approves migraine pill as preventative treatment

Migraine treatment Nurtec, developed by US firm Biohaven, is now approved for preventative and acute use.
Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix
Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT

The preventative treatment industry for migraines has gained a new player in the form of US-based firm Biohaven, which can now start competing with companies like Lundbeck, Amgen and Eli Lilly following a recent FDA approval.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading